Four Gaucher disease type II patients with three novel mutations: a single centre experience from Turkey
Makaleler > Tam Makale · 2018
Yazarlar: FATMA DERYA BULUT, Deniz Kor, Berna SEKER-YILMAZ, Ozlem Herguner, Serdar CEYLANER, Feriştah Ferda ÖZKINAY, Sebile Kilavuz, Neslihan Onenli-Mungan
Metabolic Brain Disease, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2018, cilt 33, ss 1223-1227
DOI: 10.1007/s11011-018-0236-0
Özet
Gaucher disease is the most common lysosomal storage disorder due to glucosylceramidase enzyme deficiency. There are three subtypes of the disease. Neurological involvement accompanies visceral and haematological findings only in type II and type III Gaucher patients. Type II is the acute progressive neuronopathic form which is the most severe and rare subtype. Clinical findings are recognized prenatally or in the first months of life and followed by death within the first two years of age. Among our 81 Gaucher patients, we identified 4 (4,9%) type II patients in our metabolic centre. This rate is significantly higher than the rate reported in the literature (< 1%). Three of the patients had novel mutations, one of them was a collodion baby and the other one was mistyped as type III due to its atypical presentation at the beginning and he was treated with ERT for 8 months. In this report, we present our type II Gaucher patients with three novel mutations and one perinatal lethal form with generalized ichthyosis which is a very rare disorder. Additionally, we would like to highlight the phenotypic heterogeneity not only between the subtypes, also even in the same type.